Gel shield aims to spare men painful bowel damage from prostate cancer treatment
NCT ID NCT04905069
Summary
This study is testing whether a temporary gel called SpaceOAR Vue can protect the bowel from damage during a precise type of radiation therapy for prostate cancer. The goal is to see if the gel reduces serious bowel side effects like pain, bleeding, or diarrhea that can occur months after treatment. It involves 500 men with intermediate-risk prostate cancer who are scheduled to receive stereotactic body radiotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria di Parma
Parma, 43126, Italy
-
Belfast City Hospital
Belfast, BT9 7AB, United Kingdom
-
Bon Secours Radiotherapy Cork
Cork, T12 DV56, Ireland
-
Bristol Haematology and Oncology Centre
Bristol, BS2 8ED, United Kingdom
-
Calvary Mater Newcastle
Waratah, New South Wales, 2298, Australia
-
Derriford General Hospital
Plymouth, PL6 8DH, United Kingdom
-
Dr. John Sylvester
Myrtle Beach, South Carolina, 29572, United States
-
Florida Urology Partners, LLC
Tampa, Florida, 33609, United States
-
GenesisCare USA
Fort Myers, Florida, 33908, United States
-
GenesisCare USA
Troy, Michigan, 48098, United States
-
GenesisCare, Hospital San Francisco de Asis
Madrid, 28002, Spain
-
Hospital Universitario Cruces
Barakaldo, 48903, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
IRCCS Ospedale Sacro Cuore Don Calabria
Verona, 37024, Italy
-
Inselspital - University Hospital Bern
Bern, 3010, Switzerland
-
Institut Gustave Roussy
Villejuif, Cedex, 94805, France
-
Institut de Radiothérapie & Radiochirurgie HARTMANN
Levallois-Perret, 92300, France
-
Kansas University Medical Center
Kansas City, Kansas, 66160, United States
-
Klinikum Nurnberg Nord
Nuremberg, 90419, Germany
-
MEDICLIN Robert Janker Klinik
Bonn, D-53129, Germany
-
New Jersey Urology, a Summit Health Company
Bloomfield, New Jersey, 07003, United States
-
Norfolk and Norwich University Hospital NHS Trust
Norwich, NR4 7UY, United Kingdom
-
Policlinico Universitario Agostino Gemelli
Rome, Italy
-
Princess Alexandra Hospital - ROPAIR
Woolloongabba, Queensland, 4102, Australia
-
Royal Marsden Hospital
London, SW3 6JJ, United Kingdom
-
Royal Surrey County Hospital NHS Foundation Trust
Guildford, Surrey, GU27XX, United Kingdom
-
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
-
University Hospital Basel
Basel, CH-4031, Switzerland
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
Velindre Cancer Centre
Cardiff, Wales, CF14 2TL, United Kingdom
Conditions
Explore the condition pages connected to this study.